Browse by category

Ascletis has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application (IND) to the FDA for ASC37 oral tablets for the treatment of obesity in the second quarter of 2026. ASC37 oral tablets is the company's first incretin drug candidate developed with its proprietary Peptide Oral Transport ENhancement Technology (POTENT). ASC37, a GLP-1R, GIPR,